Clinical trials: Semaglutide
Type 2 Diabetes Mellitus (T2DM)
A Study of BGM0504 in Participants With Type 2 Diabetes
This trial is conducted in China. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin and/or sulfonylureas in patients with type 2 diabetes
- Trial name
- NCT06716216
- Testing
- Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC
- Where
- China
- Volunteers
- 537 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes
A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus
This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.
- Trial name
- NCT06256549
- Testing
- GZR18, Semaglutide
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Cardiovascular Disease
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease.
- Trial name
- REDEFINE 3 (NCT05669755)
- Testing
- Cagrilintide, Semaglutide
- Where
- 633 sites in United States, Argentina and 23 more
- Volunteers
- 7,101 people
- Sponsor
- Novo Nordisk A/S
Duchenne Muscular Dystrophy (DMD)
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death.
- Trial name
- NCT07642635
- Testing
- Semaglutide (Rybelsus®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University Medical Center
Obesity & Overweight
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity.
- Trial name
- NCT07622810
- Testing
- Bofanglutida, Semaglutide
- Where
- 6 sites in Mexico
- Volunteers
- 352 people
- Sponsor
- Carnot Laboratories
Diabetes Mellitus, Type 2
A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF Therapy
The objective of this study is to evaluate the safety, feasibility and efficacy of pulsed electric field induced duodenal mucosal regeneration (with the Endogenex System en Gen 2 Device) combined with a GLP-1 receptor agonist…
- Trial name
- EMINENT-2 (NCT05984238)
- Testing
- PEF therapy using the Endogenex Device, Semaglutide, 1.0 mg/mL
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Healthy Volunteers, High Blood Cholesterol Levels
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
In this study, four new tablet versions of two compounds will be investigated. The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet…
- Conditions
- Healthy Volunteers, High Blood Cholesterol Levels, Type 2 Diabetes
- Trial name
- NCT05129891
- Testing
- Semaglutide D, Semaglutide G, Semaglutide H
- Where
- 2 sites in Canada, Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines.
- Trial name
- REDEFINE 1 (NCT05567796)
- Testing
- Cagrilintide, Semaglutide
- Where
- 256 sites in United States, Argentina and 21 more
- Volunteers
- 3,400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy.
- Trial name
- NCT07732218
- Testing
- Semaglutide (Ozempic®)
- Where
- Pakistan
- Volunteers
- 95 people
- Sponsor
- Rehman Medical Institute - RMI
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic